Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19056056 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID MODIFICATIONS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 18777597 | SPLIT COMPLEMENTARY BASE EDITING SYSTEMS BASED ON BIMOLECULAR DEAMINASES AND USES THEREOF | July 2024 | April 2025 | Allow | 9 | 0 | 1 | Yes | No |
| 18612868 | DETECTION OF NUCLEIC ACID AND NON-NUCLEIC ACID TARGET MOLECULES | March 2024 | July 2024 | Allow | 4 | 1 | 0 | No | No |
| 18392905 | CASZ COMPOSITIONS AND METHODS OF USE | December 2023 | December 2024 | Allow | 12 | 1 | 1 | No | No |
| 18377294 | DETECTION OF NUCLEIC ACID AND NON-NUCLEIC ACID TARGET MOLECULES | October 2023 | March 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18448713 | EXOSOME-TARGETED DNA VACCINE | August 2023 | February 2025 | Allow | 19 | 2 | 0 | No | No |
| 18302247 | COMPOSITIONS AND METHODS FOR RNA SYNTHESIS | April 2023 | May 2024 | Allow | 13 | 2 | 1 | Yes | No |
| 18150661 | Encoded Dual-Probe Endonuclease Assays | January 2023 | June 2025 | Allow | 29 | 4 | 0 | No | No |
| 18150669 | Encoded Endonuclease Assays | January 2023 | June 2025 | Allow | 29 | 4 | 0 | No | No |
| 18147408 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | December 2022 | January 2024 | Allow | 12 | 1 | 1 | No | No |
| 18057588 | ATTENUATED STRAIN OF AFRICAN SWINE FEVER VIRUS (ASFV) WITH IPTG-INDUCED DELETION OF D1133L GENE AND USE THEREOF | November 2022 | January 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 17990565 | DETECTION ASSAYS | November 2022 | March 2025 | Abandon | 28 | 2 | 1 | No | Yes |
| 18052791 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING LACTATE DEHYDROGENASE A (LDHA) AND USES THEREOF | November 2022 | November 2023 | Allow | 12 | 1 | 1 | No | No |
| 18049291 | KINETICALLY ENHANCED ENGINEERED FnCas9 AND ITS USES THEREOF | October 2022 | December 2023 | Allow | 14 | 1 | 1 | Yes | No |
| 17795815 | IMPROVED DETECTION ASSAYS | July 2022 | May 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17846503 | IN VITRO ASSEMBLY OF ANELLOVIRUS CAPSIDS ENCLOSING RNA | June 2022 | May 2025 | Abandon | 34 | 4 | 1 | Yes | No |
| 17692508 | RECOMBINANT EXPRESSION VECTOR FOR HIGH EXPRESSION OF BRAZZEIN IN SACCHAROMYCES CEREVISIAE AND METHOD FOR MASS-PRODUCTION OF BRAZZEIN USING THE SAME | March 2022 | May 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17683343 | METHODS FOR ENHANCED BIOSYNTHESIS AND SCREENING OF ANTIBIOTICS | February 2022 | August 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17587925 | EXOSOME-TARGETED DNA VACCINE | January 2022 | October 2024 | Allow | 32 | 3 | 1 | No | No |
| 17582102 | PHOTOSELECTIVE NON-INVASIVE TARGETED GENOMIC AND EPIGENOMIC SEQUENCING OF SPATIALLY-DEFINED CELLS OR SUBCELLULAR REGIONS | January 2022 | February 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17552423 | Xylanase Variants and Methods | December 2021 | April 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17546515 | Protein Engineering via Error-Prone Orthogonal Replication and Yeast Surface Display | December 2021 | November 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17520517 | CRISPR GENE EDITING FOR AUTOSOMAL DOMINANT DISEASES | November 2021 | July 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17519670 | ISOTHERMAL AMPLIFICATION AND AMBIENT VISUALIZATION IN A SINGLE TUBE FOR THE DETECTION OF SARS-COV-2 USING LOOP-MEDIATED AMPLIFICATION AND CRISPR TECHNOLOGY | November 2021 | December 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17600867 | CLONING AND EXPRESSION OF IN VIVO REFOLDED ANTIBODY FRAGMENT | October 2021 | May 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17482884 | CRISPR/CAS9 IN VITRO KIT | September 2021 | July 2024 | Abandon | 34 | 3 | 0 | No | No |
| 17436048 | T:A TO A:T BASE EDITING THROUGH ADENOSINE METHYLATION | September 2021 | June 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17429051 | ATTENUATION OF BACTERIAL INFECTION | August 2021 | July 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17395773 | MYOSIN 15 PROMOTERS AND USES THEREOF | August 2021 | November 2024 | Allow | 39 | 1 | 0 | No | No |
| 17357915 | METHODS FOR HIGH-THROUGHPUT SCREENING FOR GENES RELATING TO CELLULAR DIFFERENTIATION | June 2021 | January 2025 | Abandon | 43 | 3 | 1 | Yes | No |
| 17298317 | METHODS OF MODULATING RNA | May 2021 | October 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17297727 | Chimeric Promoter For Use In Metabolic Engineering | May 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17324383 | METHODS AND SYSTEMS FOR DETECTION OF KIDNEY DISEASE OR DISORDER BY GENE EXPRESSION ANALYSIS | May 2021 | March 2024 | Abandon | 34 | 2 | 1 | Yes | No |
| 17320021 | DEMAND SYNTHESIS OF POLYNUCLEOTIDE SEQUENCES | May 2021 | April 2024 | Allow | 35 | 3 | 0 | Yes | No |
| 17243079 | CRISPR-LpCas9 GENE EDITING SYSTEM AND APPLICATION THEREOF | April 2021 | January 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17227372 | Episomal expression, genomic integrated lentiviral vector expression and mRNA expression of Potent Immunoglobulins Including Dimeric Immunoglobulin A1 and A2 via a furin cleavage site and 2A self-processing peptide to Enable Mucosal and Hematological Based Immunity or Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. | April 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17203724 | RAPID DIAGNOSTIC TEST | March 2021 | January 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17202202 | Riboregulated Switchable Feedback Promoter Systems and Methods | March 2021 | June 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17276317 | ENDONUCLEASE 1 RIBONUCLEASES FOR CLEANING | March 2021 | July 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17273402 | Method for Detecting in a Cell RNA-Protein Interaction | March 2021 | November 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17187666 | CRISPR/CAS9 SYSTEMS, AND METHODS OF USE THEREOF | February 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17182352 | METHOD OF USING CUT&RUN OR CUT&TAG TO VALIDATE CRISPR-CAS TARGETING | February 2021 | June 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17168950 | MOLECULAR ANALYSES USING LONG CELL-FREE FRAGMENTS IN PREGNANCY | February 2021 | June 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17164632 | Use of Combinatorial Non-Coding DNA Snippets as Taggants in Consumer Products and Supply Chains | February 2021 | January 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17160561 | Method for Constructing Efficient Bacillus Subtilis Promoter | January 2021 | September 2024 | Allow | 43 | 1 | 1 | No | No |
| 17161267 | FLEXIBLE DETECTION SYSTEMS | January 2021 | June 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17264094 | PROBE/PRIMER LIBRARY FOR DIAGNOSIS OF CANCER | January 2021 | July 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17133300 | METHOD FOR KNOCKING OUT N-MYRISTOYLTRANSFERASE (NMT) GENE FROM EIMERIA TENELLA | December 2020 | July 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17253401 | GENE EXPRESSION CASSETTE CAPABLE OF INITIATING TRANSLATION AFTER COMPLETION OF TRANSCRIPTION FOR PRODUCING HIGH-QUALITY RECOMBINANT PROTEIN IN BACTERIA | December 2020 | August 2024 | Allow | 43 | 1 | 0 | Yes | No |
| 17058454 | A METHOD OF STORING INFORMATION USING DNA MOLECULES | November 2020 | May 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17053265 | CRISPR TRANSIENT EXPRESSION CONSTRUCT (CTEC) | November 2020 | July 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17052609 | ENGINEERED CELLS WITH MODIFIED HOST CELL PROTEIN PROFILES | November 2020 | January 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17073165 | THERMOFLUIDICS FOR SPATIAL CONTROL OF GENE ACTIVATION | October 2020 | January 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17020676 | NEAR-INFRARED PHOTOTHERMALLY ACTIVATED CRISPR/CAS9 GENOME EDITING MACHINE | September 2020 | June 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17013420 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | September 2020 | June 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17011994 | Plasmid Vector for Expressing mRNA in Vitro, Construction Method and Application Thereof | September 2020 | January 2024 | Abandon | 41 | 2 | 0 | Yes | No |
| 16971044 | NANO-VESICLE DERIVED FROM CATENIBACTERIUM BACTERIA AND USE THEREOF | August 2020 | February 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 16970115 | CELL DATA RECORDERS AND USES THEREOF | August 2020 | March 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 16968899 | NOVEL CAS9 ORTHOLOGS | August 2020 | March 2024 | Abandon | 43 | 1 | 1 | No | No |
| 16967595 | TLR9 INHIBITORS TO SUPPRESS INFLAMMATORY RESPONSE TO PATHOGENS | August 2020 | May 2024 | Allow | 45 | 1 | 0 | No | No |
| 16944584 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS (HSV) RELATED KERATITIS | July 2020 | May 2025 | Abandon | 58 | 2 | 1 | No | No |
| 16940180 | Gold Optimized CAR T-cells | July 2020 | January 2025 | Abandon | 54 | 2 | 0 | No | No |
| 16963529 | MDA-7/IL -24 SECRETORY VARIANTS AND METHODS OF USE | July 2020 | September 2024 | Allow | 50 | 1 | 1 | Yes | No |
| 16913226 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | June 2020 | August 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16894359 | FRAMESHIFT SUPPRESSOR tRNA COMPOSITIONS AND METHODS OF USE | June 2020 | August 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16765604 | POLYNUCLEOTIDES ENCODING ORNITHINE TRANSCARBAMYLASE FOR THE TREATMENT OF UREA CYCLE DISORDERS | May 2020 | August 2023 | Allow | 39 | 0 | 1 | Yes | No |
| 16758458 | METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING INTRACRANIAL ANEURYSM | April 2020 | March 2024 | Abandon | 47 | 2 | 0 | No | No |
| 16744130 | MODELING RIBOSOME DYNAMICS TO OPTIMIZE HETEROLOGOUS PROTEIN PRODUCTION | January 2020 | August 2024 | Allow | 55 | 2 | 1 | Yes | No |
| 16631157 | APPLICATION OF CAS PROTEIN, METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULE AND KIT | January 2020 | August 2024 | Allow | 55 | 2 | 1 | Yes | No |
| 16619697 | METHODS FOR IDENTIFYING ACTIVATORS AND SUPPRESSORS | December 2019 | May 2023 | Abandon | 41 | 1 | 0 | No | No |
| 16704190 | NUCLEIC ACID SYNTHESIS TECHNIQUES | December 2019 | May 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16605770 | HUMAN GENE CORRECTION | October 2019 | February 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16563274 | DIRECT CLONING | September 2019 | August 2024 | Allow | 60 | 3 | 0 | No | No |
| 16486099 | COMPOSITIONS AND METHODS FOR REGULATING IMMUNE SYSTEM ACTIVITY | August 2019 | June 2024 | Abandon | 58 | 0 | 1 | No | No |
| 16434102 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID PROCESSING USING BLOCKING AGENTS | June 2019 | August 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16415179 | METHODS FOR THE IDENTIFICATION OF VARIANT RECOGNITION SITES FOR RARE-CUTTING ENGINEERED DOUBLE-STRAND-BREAK-INDUCING AGENTS AND COMPOSITIONS AND USES THEREOF | May 2019 | February 2024 | Abandon | 57 | 2 | 1 | Yes | No |
| 16347880 | HIGHLY EFFICIENT AND TUNABLE SYSTEM FOR THE INCORPORATION OF UNNATURAL AMINO ACIDS INTO PROTEINS IN ESCHERICHIA COLI | May 2019 | July 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16327521 | Novel Modification of 5-Methylcytosine Catalyzed by CMD1 Enzyme and Application Thereof | March 2019 | March 2024 | Allow | 60 | 1 | 1 | Yes | No |
| 16282498 | NOVEL CAS9 ORTHOLOGS | February 2019 | April 2024 | Allow | 60 | 1 | 1 | No | No |
| 16315846 | SCRaMbLE OF HETEROZYGOUS DIPLOID YEAST | January 2019 | September 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16209706 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | December 2018 | August 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16095236 | Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four | October 2018 | April 2024 | Abandon | 60 | 2 | 1 | No | No |
| 15978618 | Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax | May 2018 | December 2023 | Abandon | 60 | 3 | 0 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner REGA, KYLE THOMAS.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner REGA, KYLE THOMAS works in Art Unit 1636 and has examined 80 patent applications in our dataset. With an allowance rate of 53.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner REGA, KYLE THOMAS's allowance rate of 53.8% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by REGA, KYLE THOMAS receive 1.65 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by REGA, KYLE THOMAS is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +58.8% benefit to allowance rate for applications examined by REGA, KYLE THOMAS. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 40.0% of cases where such amendments are filed. This entry rate is in the 53% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 34.5% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.7% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.